SU5416 and SU6668 inhibit biological functions of c-kit in a myeloid leukemia cell line and in AML blasts.

被引：0
|
作者：
Smolich, BD
Yuen, HA
West, KA
Giles, FJ
Albitar, M
Cherrington, JM
机构：
[1] Sugen, S San Francisco, CA 94080 USA
[2] MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
CLINICAL CANCER RESEARCH | 2000年 / 6卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
265
引用
收藏
页码：4519S / 4519S
页数：1
相关论文
共 13 条
  • [1] SU5416 and SU6668 inhibit c-kit signaling and induce apoptosis in a human myeloid cell line and in AML blasts.
    West, KA
    Yuen, HA
    Smolich, BD
    Giles, FJ
    Albitar, M
    Cherrington, JM
    BLOOD, 2000, 96 (11) : 102A - 102A
  • [2] The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts
    Smolich, BD
    Yuen, HA
    West, KA
    Giles, FJ
    Albitar, M
    Cherrington, JM
    BLOOD, 2001, 97 (05) : 1413 - 1421
  • [3] SU5416,a novel receptor tyrosine kinase inhibitor, in the treatment of patients with refractory, c-kit positive, acute myeloid leukemia.
    Fiedler, W
    Mesters, R
    Staib, P
    Kuse, R
    Duehrsen, U
    Flasshove, M
    Truemper, L
    Cavalli, F
    Ottmann, O
    Kelsey, S
    Scigalla, P
    Loges, S
    Tinnefeld, H
    Hossfeld, DK
    Berdel, WE
    BLOOD, 2001, 98 (11) : 124A - 124A
  • [4] Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668
    Davis, DW
    Takamori, R
    Raut, CP
    Xiong, HQ
    Herbst, RS
    Stadler, WM
    Heymach, JV
    Demetri, GD
    Rashid, A
    Shen, Y
    Wen, SJ
    Abbruzzese, JL
    McConkey, DJ
    CLINICAL CANCER RESEARCH, 2005, 11 (02) : 678 - 689
  • [5] Downregulation of VEGF-A, STAT5 and AKT in acute myeloid leukemia blasts of patients treated with SU5416
    Loges, Sonja
    Tinnefeld, Heike
    Metzner, Anja
    Juecker, Manfred
    Butzal, Martin
    Bruweleit, Melanie
    Fischer, Uta
    Draab, Elena
    Schuch, Gunter
    O'-Farrel, Anne Marie
    Hossfeld, Dieter Kurt
    Bokemeyer, Carsten
    Fiedler, Walter
    LEUKEMIA & LYMPHOMA, 2006, 47 (12) : 2601 - 2609
  • [6] SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro
    Abdollahi, A
    Lipson, K
    Han, X
    Krempien, R
    Trinh, T
    Weber, KJ
    Hahnfeldt, P
    Hlatky, L
    Howlett, AR
    Debus, J
    Huber, PE
    STRAHLENTHERAPIE UND ONKOLOGIE, 2003, 179 (09) : 658 - 658
  • [7] SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro
    Abdollahi, A
    Lipson, KE
    Han, XH
    Krempien, R
    Trinh, T
    Weber, KJ
    Hahnfeldt, P
    Hlatky, L
    Debus, J
    Howlett, AR
    Huber, PE
    CANCER RESEARCH, 2003, 63 (13) : 3755 - 3763
  • [8] Molecular targeting in acute myeloid leukemia (AML) therapy: APcK110 is a new inhibitor of c-Kit activity in AML blasts
    Faderl, S.
    Bornmann, W.
    Maxwell, D.
    Peng, Z.
    Van, Q.
    Liu, Z.
    Verstovsek, S.
    Ferrajoli, A.
    Kantarjian, H. M.
    Estrov, Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] The tyrosine kinase inhibitor SU5416 reduces proliferation and colony-formation of primary AML blasts after co-culture with a newly derived endothelial feeder cell line.
    Fiedler, W
    Mende, T
    Tinnefeld, H
    Philippe, S
    Gehling, U
    Vohwinkel, G
    Scigalla, P
    Hossfeld, DK
    BLOOD, 2000, 96 (11) : 122A - 122A
  • [10] CELL-SURFACE EXPRESSION OF C-KIT RECEPTORS BY CHILDHOOD ACUTE MYELOID-LEUKEMIA BLASTS IS NOT OF PROGNOSTIC VALUE - A REPORT FROM THE CHILDRENS CANCER GROUP
    SMITH, FO
    BROUDY, VC
    ZSEBO, KM
    LAMPKIN, BC
    BUCKLEY, CV
    BUCKLEY, JD
    OPIE, T
    WOODS, WG
    HAMMOND, GD
    BERNSTEIN, ID
    BLOOD, 1994, 84 (03) : 847 - 852
12